Over-expression of miR-588 significantly suppressed the luciferase activity of reporter plasmid containing the wild type 3'UTR sequences of Cyclin A2 complementary to miR-588, which was abolished by mutations in these 3'UTR regions. miR-588 overexpression also significantly reduced the expression of Cyclin A2 at both mRNA and protein levels. A significant decrease in the expression of various cell cycle pathway genes such as CycE1, MCM2, MCM4, CDC7 and CDT1 was also observed. These genes are involved in promoting cell cycle and proliferation and are overexpressed in prostate cancer. In vivo intracardiac implantation of PC3-MLuc-C6 prostate cancer cells constitutively expressing miR-588 showed a significant inhibition of the metastatic dissemination of these cells compared to the control miR expressing cells.
INTRODUCTION AND OBJECTIVES:
Although single nucleotide polymorphisms (SNPs) are associated with the risk of prostate cancer (PCa), scarce data is available on to the association between SNPs and the risk of adverse pathology. The aim of this study was to identify a group of SNPs associated with an increased risk of aggressive PCa in a prospective cohort of patients undergoing radical prostatectomy (RP) METHODS: Overall, 247 consecutive patients with localized PCa treated with RP and extended pelvic lymph node dissection (ePLND) at a single center were evaluated. After IRB approval, whole blood genomic DNA (gDNA) was extracted and amplified using Haloplex custom designed-gene panels covering the exons of 78 genes and 128 SNPs in intergenic regions previously reported to be associated with PCa. Of more than 2,000 variants evaluated, 26 SNPs resulted to be linked to PCa in a larger country specific population study were analyzed. Fluidigm Access Array System (Fluidigm, San Francisco, CA, USA) was used to amplify target regions associated with PCa. High-throughput sequencing was performed using the Illumina MiSeq platform. Pathologic specimens were evaluated by a high-volume uro-pathologist. A comprehensive approach was used to test in univariable analyses all available SNPs associated with an increased risk of pathological grade group 4-5, pT3b/4 disease and lymph node invasion (LNI). Multivariable logistic regression analyses tested the association between SNPs and adverse RP features after adjusting for confounders RESULTS: Overall, 53 (21.5%), 32 (13%) and 28 (11.3%) patients had pathologic grade group 4-5, LNI and pT3b/4 disease. At univariable analysis, the genotype A of the androgen receptor (AR) gene rs6152, which was present in 45 (18.2%) patients, was the only significantly associated with an increased risk of pathologic grade group 4-5 and pT3b/4 disease (all p<0.05). Of note, 15 (33.3%) vs. 38 (18.8%) patients with the genotype A vs. G had grade group 4-5 disease (p¼0.02). Similarly, 9 (20%) vs. 19 (9.4%) patients with the genotype A vs. G had pT3b/4 disease (p¼0.04). At multivariable analysis, the genotype A of rs6152 was associated with an increased risk of pathologic grade group 4-5 (OR: 1.99; 95% CI: 1.03-4.31) and pT3b/4 (OR: 2.66; 95%CI: 1.04-5.82) disease CONCLUSIONS: Using a large and comprehensive approach, we showed that rs6152A was a predictor of adverse pathology at RP such as pathologic grade group 4-5 and pT3b/4 PCa. These data emphasizes the pivotal role of AR in PCa development and progression Source of Funding: none
MP29-18 THE EPH FAMILY OF RECEPTOR TYROSINE KINASES AS TUMOR SUPPRESSORS IN AFRICAN-AMERICANS WITH PROSTATE CANCER
Albert H Kim*, Jane Nguyen, Mark Schluchter, Bingcheng Wang, Carvell Nguyen, Cleveland, OH INTRODUCTION AND OBJECTIVES: The Eph receptors are the largest family of receptor tyrosine kinases in humans and are involved in key cellular processes in prostate carcinogenesis including malignant transformation and metastasis. However, the role of Eph receptors has yet to be defined. In vitro studies in well-characterized prostate cancer (PCa) cell lines demonstrate Eph expression to vary from highly expressed (oncogene) to lost (tumor suppressor). Limited studies in human PCa tissue mirror these findings. Understanding differences in molecular mechanisms in African American (AA) men is particularly important as they are disproportionately affected by aggressive PCa. Here, we investigate the role of EPH genes in the pathogenesis of PCa in AAs.
METHODS: RNA was isolated from 12 patients who underwent radical prostatectomy at MetroHealth (Cleveland, OH) from 2013-2017. Benign and malignant tissue pairs from each patient was used for comparisons. Clinical characteristics are described in Table 1 . Realtime PCR was performed for 14 Eph genes (EPHA1-EPHA7, EPHB1, EPHB2, EPHB4, EPHB6, EFNA1, EFNA5, and EFNB2). Fold-change (FC) was calculated and groups were compared using Wilcoxon rank sum and signed rank tests (p-values). The false discovery rate method was used to adjust for multiple testing (q-values).
RESULTS: In combined analysis of all prostatectomy specimens, EPHA2 (FC¼0.27), EPHA3 (FC¼0.38), EPHA4 (FC¼0.40), EPHA7 (FC¼0.32), EPHB1 (FC¼0.16), EPHB2 (FC¼0.35), and EFNA5 (FC¼0.45) were downregulated in malignant versus benign tissue (all p<.02; q¼.036). In AA prostatectomy specimens, EPHA1 (FC¼0.5), EPHA2 (FC¼0.26), EPHA4 (FC¼0.28) and EFNA5 (FC¼0.37) were downregulated in malignant versus benign tissue (all p¼0.03; q¼0.09). Finally, comparing malignant AA to malignant Caucasian (CA) specimens, EPHA1 (FC¼0.33) was downregulated in AAs (p¼0.04; q¼0.52).
CONCLUSIONS: Multiple members of the Eph gene family are significantly downregulated in AA men with prostate cancer. EPHA1 in particular was significantly downregulated when comparing malignant AA to malignant CA specimens and could serve as a novel biomarker in AAs. These data support a generally ligand-dependent tumor suppressor function of Eph receptors and warrants further investigation in the biological mechanism behind PCa disparities in AA men.
Source of Funding: DOD grant award number: W81XWH-14-1-0546 e372 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
